Animal models and animal-free innovations for cardiovascular research : current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissionsoup.com..
Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Cardiovascular research - 118(2022), 15 vom: 09. Dez., Seite 3016-3051 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Big data |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cvr/cvab370 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335351034 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335351034 | ||
| 003 | DE-627 | ||
| 005 | 20240214232411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cvr/cvab370 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM335351034 | ||
| 035 | |a (NLM)34999816 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van der Velden, Jolanda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Animal models and animal-free innovations for cardiovascular research |b current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Big data | |
| 650 | 4 | |a Bioinformatics | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Multiomics | |
| 650 | 4 | |a Network medicine | |
| 650 | 4 | |a Tissue engineering | |
| 650 | 4 | |a iPSC | |
| 700 | 1 | |a Asselbergs, Folkert W |e verfasserin |4 aut | |
| 700 | 1 | |a Bakkers, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Batkai, Sandor |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Bezzina, Connie R |e verfasserin |4 aut | |
| 700 | 1 | |a Bot, Ilze |e verfasserin |4 aut | |
| 700 | 1 | |a Brundel, Bianca J J M |e verfasserin |4 aut | |
| 700 | 1 | |a Carrier, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Chamuleau, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarelli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Sean M |e verfasserin |4 aut | |
| 700 | 1 | |a Dendorfer, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Duncker, Dirk J |e verfasserin |4 aut | |
| 700 | 1 | |a Eschenhagen, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Fabritz, Larissa |e verfasserin |4 aut | |
| 700 | 1 | |a Falcão-Pires, Ines |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdinandy, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Giacca, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Girao, Henrique |e verfasserin |4 aut | |
| 700 | 1 | |a Gollmann-Tepeköylü, Can |e verfasserin |4 aut | |
| 700 | 1 | |a Gyongyosi, Mariann |e verfasserin |4 aut | |
| 700 | 1 | |a Guzik, Tomasz J |e verfasserin |4 aut | |
| 700 | 1 | |a Hamdani, Nazha |e verfasserin |4 aut | |
| 700 | 1 | |a Heymans, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Hilfiker, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Hilfiker-Kleiner, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Hoekstra, Alfons G |e verfasserin |4 aut | |
| 700 | 1 | |a Hulot, Jean-Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Kuster, Diederik W D |e verfasserin |4 aut | |
| 700 | 1 | |a van Laake, Linda W |e verfasserin |4 aut | |
| 700 | 1 | |a Lecour, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Leiner, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Linke, Wolfgang A |e verfasserin |4 aut | |
| 700 | 1 | |a Lumens, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Lutgens, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Madonna, Rosalinda |e verfasserin |4 aut | |
| 700 | 1 | |a Maegdefessel, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Mayr, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a van der Meer, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Passier, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Perbellini, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Perrino, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Pesce, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Priori, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Remme, Carol Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenhahn, Bodo |e verfasserin |4 aut | |
| 700 | 1 | |a Schotten, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Sipido, Karin R |e verfasserin |4 aut | |
| 700 | 1 | |a Sluijter, Joost P G |e verfasserin |4 aut | |
| 700 | 1 | |a van Steenbeek, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Steffens, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Terracciano, Cesare M |e verfasserin |4 aut | |
| 700 | 1 | |a Tocchetti, Carlo Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Vlasman, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Kak Khee |e verfasserin |4 aut | |
| 700 | 1 | |a Zacchigna, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Zwaagman, Dayenne |e verfasserin |4 aut | |
| 700 | 1 | |a Thum, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular research |d 1967 |g 118(2022), 15 vom: 09. Dez., Seite 3016-3051 |w (DE-627)NLM000080209 |x 1755-3245 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2022 |g number:15 |g day:09 |g month:12 |g pages:3016-3051 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cvr/cvab370 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2022 |e 15 |b 09 |c 12 |h 3016-3051 | ||